SELLAS Life Sciences Group, Inc. has been granted Orphan Drug Designation by the EMA for its CDK9 inhibitor, SLS009, for treating relapsed/refractory peripheral T-cell lymphomas. This designation could expedite the drug's development and approval process, potentially leading to increased investor interest and a positive short-term impact on the stock price.